Brian W. Loggie, MD, CM, FRCSC, FACS

Creighton University Medical Center (CUMC), Omaha, NE

Brian W. Loggie, MD, CM, FRCSC, FACS

Harold J. Bonnstetter Professor of Surgery Chief, Division of Surgical Oncology Creighton University Medical Center.

Dr. Brian Loggie has a national and international reputation for his expertise and experience in treating cancers metastatic to or arising from the peritoneal lining surfaces of the abdomen and pelvis. 

UNDERGRADUATE DEGREE:
CEGEP Diploma, Science, 1973;
Pre-med Loyola College, Montreal, Canada, 1974,

MEDICAL DEGREE:
M.D., C.M., McGill University, Montreal, Canada, 1979,

POSTGRADUATE TRAINING:
Internship, Department of Surgery, Montreal General Hospital, Montreal, Canada, 1979-80,
Resident in Surgery, Department of Surgery, Montreal General Hospital, Montreal, Canada, 1980-86,
Graduate Studies, Department of Experimental Surgery, McGill University, Montreal, Canada, 1982-86,

SPECIALTY TRAINING:
Clinical and Research Fellowship in Surgical Oncology, Division of Surgical Oncology, Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, 1986-88,
Specialist Certificate in General Surgery, Royal College of Physicians and Surgeons of Canada, 1986,
Diplomat of the American Board of Surgery, 1990,
Certificate of Training in Surgical Oncology issued from University of Illinois School of Medicine, Department of Surgery, Chicago, Illinois, 1998,
Re-certification, American Board of Surgery, General Surgery 1998,

SPECIAL INTERESTS / EXPERTISE:
Surgical Oncology. Peritoneal carcinomatosis and malignant ascites, peritoneal mesothelioma, abdominopelvic and retroperitoneal sarcomas, pseudomyxoma peritonei, cutaneous malignant melanoma, sphincter preserving treatment for rectal tumors, and management of complex primary or recurrent solid tumors,

ORGANIZATIONS / SOCIETIES:
Fellow, Royal College of Surgeons of Canada;
Fellow, Society of Surgical Oncology;
Fellow, American College of Surgeons;
Fellow, Southeastern Surgical Congress;
Member, Canadian Association of General Surgeons;
Member, North Carolina Medical Society;
Member, Forsyth-Stokes-Davie County Medical Society;
Member, Association for Academic Surgery;
Member, American Medical Association;
Member, Bowman Gray Surgical Society;
Member New York Academy of Sciences;
Member, North Carolina Chapter, American College of Surgeons;
Member, Cancer and Leukemia Group B(CALGB);
Member, Southern Association for Oncology;
Fellow, American College of Surgeons;
Member, United States Chapter of the Societe Internationale de Chiurgie;
Member, American Society of Clinical Oncology (ASCO);
Member, International Society for Regional Cancer Therapy;
Member, North Carolina Surgical Association;
Director, Mesothelioma Applied Research Foundation (MARF),

HONORS:
Consolidated-Bathurst Ltd. Academic Scholarship Award (awarded in 1973; renewed annually for duration of undergraduate and medical studies at McGill);
Medical Research Council of Canada Fellowship to pursue studies in experimental surgery(awarded 1981 and renewed annually to 1983-84);
McGill University, Department of Experimental Surgery Research Seminar, Third Prize-1983;
McGill University, Department of Experimental Surgery Research Seminar, First Prize-1984;
Canadian Association of General Surgeons National Prize for Resident Research-Presented at Royal College Meeting, Montreal Canada;
Visiting Professor, New Hanover Regional Medical Center, Wilmington, North Carolina;
Elected Vice-President (USA) for International Society for Regional Cancer Therapy (ISRCT) in Ravenna, Italy.




Contacting Dr. Loggie

There are three ways you can contact this doctor

  • You can request an office consultation using the form below.
  • You can request a phone conversation by clicking here and picking a time-slot from his calendar.
  • You can call his office directly at the phone number listed on this page.


 

Dr. Brian Loggie shares details about his research in the treatment of Appendiceal Cancer and Pseudomyxoma Peritonei.

PMP Pals presents Dr. Brian Loggie, Sugical Oncologist

News Stories

Taking on rarest of cancers, and beating the odds

Publications

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.

Low grade peritoneal mucinous carcinomatosis associated with human papilloma virus infection: case report.

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.

Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy.

COX-2 expression in pseudomyxoma peritonei.

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer.

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.

Peritoneal carcinomatosis: what can we do about it?

Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.

Intraoperative modality of treatment for peritoneal carcinomatosis: use of hyperthermic interperitoneal chemoperfusion.

Malignant peritoneal mesothelioma.

Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.

Prospective trial for the treatment of malignant peritoneal mesothelioma.

Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.

CT appearance of disseminated peritoneal adenomucinosis.

Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin.

Peritoneal carcinomatosis with urachal signet-cell adenocarcinoma.

Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery.

Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy.

Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Surgical concepts in the treatment of colorectal cancer.

Complications of heated intraperitioneal chemotherapy and strategies for prevention.